Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Catalyst Pharmaceuticals Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units, which suggests that each active application is being reviewed in a separate administrative section. This distribution across 2 distinct art units indicates that the company's current applications cover different technical aspects of biotechnology. With 2 pending office actions, the company must manage 2 separate sets of deadlines and examiner requirements.
ELENISTE, PIERRE PAUL is the busiest examiner with 1 busiest examiner pending office action. Since there are 2 pending office actions in total, the workload is distributed, with ELENISTE, PIERRE PAUL managing 1 of the 2 active cases. This means that the company's prosecution efforts are split between 2 distinct examiners, each handling a single matter. The presence of 1 busiest examiner pending office action alongside 2 total actions indicates a balanced workload across the assigned examiners. Practitioners should be prepared to address the specific concerns of both ELENISTE, PIERRE PAUL and the other examiner involved in the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ELENISTE, PIERRE PAUL | 1 | 35.5% | +31.2% |
| VALLE, ERNESTO | 1 | 65.8% | +32.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17633021 | METHOD FOR TREATING SEXUAL DYSFUNCTION | VALLE, ERNESTO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17819111 | METHOD FOR TREATING BOTULINUM TOXIN POISONING | ELENISTE, PIERRE PAUL | 120d overdue |
| 17633021 | METHOD FOR TREATING SEXUAL DYSFUNCTION | VALLE, ERNESTO | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17819111 | METHOD FOR TREATING BOTULINUM TOXIN POISONING | ELENISTE, PIERRE PAUL | 1622 | §103 | Non-Final OA | 120d overdue | Pending | Aug 11, 2022 |
| 17633021 | METHOD FOR TREATING SEXUAL DYSFUNCTION | VALLE, ERNESTO | 1623 | §103§112 | Non-Final OA | — | Pending | Feb 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial